Grape Derivative for the Treatment of Obesity and for Non-alcoholic Fatty Liver Disease

Technology Overview

Obesity has reached pandemic proportions worldwide. It is estimated that about 30% of the world population is defined as obese. Obesity imposes major health challenge; it significantly increases the risk of developing co-morbid complex and chronic diseases, such as diabetes, heart disease, osteoarthritis, several cancers, as well as mortality. Researchers have estimated that by 2030, given obesity trends, obesity-related medical costs alone could rise by $48 - 66 billion per year in the U.S. 

An Israeli university have developed a new technology for the management of obesity and for non-alcoholic fatty liver disease (NAFLD). The technology is based on a proprietary grape derivative which effects body weight and NAFLD of mice on high-fat diet. This technology addresses a $2B weight management and $1B for NAFLD treatment market.

Technology Features & Specifications

The beneficial effect of moderate red wine consumption on several aspects of the metabolic syndrome, including insulin resistance, elevated blood pressure, increased coagulation and cardiovascular disease is already well established. These effects are likely to accrue due to the presence of polyphenols. However, red wine consumption has its increase alcohol consumption which might lead to drowsiness and liver disease.

This proprietary grape derivative contains high levels of polyphenols which have known health-promoting effects. The derivative has been shown to affect the body weight and NAFLD of mice on high-fat diet. 

Potential Applications

NAFLD is defined as having greater than 5% liver fat accumulation, while its accumulation may continue to develop into Non-Alcoholic Steatohepatitis (NASH). In the case of NASH the liver is permanently damaged and scarred and no longer able to work properly. There are over 100,000 children and Several million adults with NAFLD, many with diabetes. It is estimated that over 20,000 Americans with NASH will develop severe liver disease leading to transplant surgery. Importantly, there are no approved therapies for patients with either NAFLD or NASH.

Customer Benefits

Despite the unmet need, to date, pharmaceutical treatments have shown poor success rates. This technology addresses a $2B weight management and $1B for NAFLD treatment market.

Make an Enquiry